• In late May and early June 2026, Lam Research drew heightened attention as Nvidia’s Computex keynote spotlighted the Vera Rubin AI chip entering full production, while multiple research firms highlighted Lam’s role supplying critical etch and deposition tools for AI memory and advanced packaging.
• At the same time, analysts and institutional investors framed Lam less as a purely cyclical equipment vendor and more as an essential AI infrastructure provider, supported by strong free cash flow, large shareholder returns, and growing revenue tied to increasingly complex chip manufacturing nodes.
• We’ll now examine how Lam’s elevated role in the AI supply chain, underscored by Nvidia’s Vera Rubin ramp, could influence this investment narrative.

Capitalize on the AI infrastructure supercycle with our selection of the 48 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.

Lam Research Investment Narrative Recap

To be comfortable owning Lam Research, you need to believe AI-driven demand for advanced memory and packaging can offset the industry’s usual cycles, while Lam’s etch and deposition tools stay central to that spend. Nvidia’s Vera Rubin ramp reinforces the near term AI equipment story, but the key swing factor remains how long wafer fab equipment budgets stay elevated, with export controls on China still looking like the most immediate threat to Lam’s revenue mix and margins.

The most relevant recent development here is the wave of analyst upgrades around late May, including Mizuho lifting its Lam price target to US$380 and raising WFE spending estimates for 2026 and 2027. Those calls tied Lam’s outlook directly to stronger NAND node transitions, DRAM and high bandwidth memory demand, and increased TSMC spending, all of which intersect tightly with the AI infrastructure narrative highlighted by Nvidia’s Vera Rubin production ramp.

Yet even with this upbeat AI story, the implications of tightening US export controls on Lam’s China shipments are something investors should be aware of...

Lam Research's narrative projects $37.4 billion revenue and $12.4 billion earnings by 2029.

Uncover how Lam Research's forecasts yield a $313.69 fair value, a 7% downside to its current price.

Exploring Other Perspectives

Some of the most optimistic analysts were already modeling Lam’s revenue reaching about US$41.6 billion and earnings of roughly US$15.4 billion by 2029, which is a far more aggressive setup than the baseline view that emphasizes risks from export controls and China exposure; in light of the Vera Rubin news, it is worth asking whether those bullish assumptions prove closer to reality or need to be trimmed back.

Explore 9 other fair value estimates on Lam Research - why the stock might be worth less than half the current price!

Form Your Own Verdict

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Lam Research research is our analysis highlighting 3 key rewards and 1 important warning sign that could impact your investment decision.
• Our free Lam Research research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Lam Research's overall financial health at a glance.

Interested In Other Possibilities?

These stocks are moving-our analysis flagged them today. Act fast before the price catches up:

• Invest in the nuclear renaissance through our list of 88 elite nuclear energy infrastructure plays powering the global AI revolution.
• We've uncovered the 10 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.
• AI is about to change healthcare. These 40 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.